1. Home
  2. MRNS vs PBHC Comparison

MRNS vs PBHC Comparison

Compare MRNS & PBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRNS
  • PBHC
  • Stock Information
  • Founded
  • MRNS 2003
  • PBHC 1859
  • Country
  • MRNS United States
  • PBHC United States
  • Employees
  • MRNS N/A
  • PBHC N/A
  • Industry
  • MRNS Biotechnology: Pharmaceutical Preparations
  • PBHC Major Banks
  • Sector
  • MRNS Health Care
  • PBHC Finance
  • Exchange
  • MRNS Nasdaq
  • PBHC Nasdaq
  • Market Cap
  • MRNS 29.9M
  • PBHC 108.9M
  • IPO Year
  • MRNS 2014
  • PBHC N/A
  • Fundamental
  • Price
  • MRNS $0.54
  • PBHC $15.38
  • Analyst Decision
  • MRNS Buy
  • PBHC
  • Analyst Count
  • MRNS 12
  • PBHC 0
  • Target Price
  • MRNS $4.28
  • PBHC N/A
  • AVG Volume (30 Days)
  • MRNS 3.2M
  • PBHC 8.8K
  • Earning Date
  • MRNS 03-04-2025
  • PBHC 01-30-2025
  • Dividend Yield
  • MRNS N/A
  • PBHC 2.60%
  • EPS Growth
  • MRNS N/A
  • PBHC N/A
  • EPS
  • MRNS N/A
  • PBHC 0.25
  • Revenue
  • MRNS $31,466,000.00
  • PBHC $35,494,000.00
  • Revenue This Year
  • MRNS $14.97
  • PBHC N/A
  • Revenue Next Year
  • MRNS $57.65
  • PBHC N/A
  • P/E Ratio
  • MRNS N/A
  • PBHC $62.60
  • Revenue Growth
  • MRNS 1.63
  • PBHC N/A
  • 52 Week Low
  • MRNS $0.22
  • PBHC $11.41
  • 52 Week High
  • MRNS $10.50
  • PBHC $19.86
  • Technical
  • Relative Strength Index (RSI)
  • MRNS 70.61
  • PBHC 28.91
  • Support Level
  • MRNS $0.53
  • PBHC $17.06
  • Resistance Level
  • MRNS $0.56
  • PBHC $16.60
  • Average True Range (ATR)
  • MRNS 0.03
  • PBHC 0.45
  • MACD
  • MRNS 0.02
  • PBHC -0.23
  • Stochastic Oscillator
  • MRNS 94.94
  • PBHC 0.45

About MRNS Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

Share on Social Networks: